Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.
Researchers at Indiana University School of Medicine have identified a mechanism that causes inflammation in asthma and other allergic diseases, a discovery that could lead to new targets to control such allergic reactions.
ProImmune Ltd offers the CFSE T cell proliferation assays for immunogenicity risk assessment used in the design and selection of biological drug leads at the preclinical stage.
BrainCells Inc. announced that the United States Patent and Trademark Office issued the company Patent Number 7,678,808 entitled, “5 HT Receptor Mediated Neurogenesis.”
The Global Alliance for TB Drug Development (TB Alliance) and AstraZeneca announced at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB), including drug-resistant strains of the disease.
A new white paper, “Advanced Detection of Mycoplasmas: How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers,” explores relevant mycoplasma characteristics, established testing solutions, and the use of real-time PCR analysis as an alternative testing method for fast, preliminary mycoplasma detection.
BacTrace antibodies to infectious disease agents include Borrelia burgdorferi, Borrelia species, Legionella species and Helicobacter pylori.
Radix BioSolutions will integrate a Gyrolab xP workstation into its immunoassay development programs.
The Biochrom Asys UVM340 monochromator-based plate reader lets users select the exact wavelength to measure optical density for an application.
Behavioral interventions typically are the first line of treatment to manage unwanted behaviors in children with autism spectrum disorders (ASDs). If behaviors do not improve, medications frequently are added to the mix.
amsbio has introduced TRU Block, a highly potent reagent that actively blocks the heterophilic antibody (HA) interference in immunoassays including Human Anti-Mouse Antibody (HAMA) interference.
Although there is no known cause of autism, studies have shown that mutations in several genes are associated with the developmental brain disorder. New research has uncovered two additional genes that may be involved with autism.
Agilent Automation Solutions has configured its BioCel System that to allow laboratories to fully automate cell-based ELISA procedures thereby reducing the risk of human error, contamination, and time spent on tedious manual procedures.
Researchers from the University of Leeds, UK, the Charité University Medical School and the Max Delbrück Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.